XML 58 R24.htm IDEA: XBRL DOCUMENT v3.20.1
FAIR VALUE (Tables)
3 Months Ended
Mar. 31, 2020
Fair Value Disclosures [Abstract]  
Schedule of Financial Assets Measured at Fair Value on Recurring Basis
The following table summarizes our fair value measurements at March 31, 2020 and December 31, 2019, respectively, for financial assets measured at fair value on a recurring basis:
 
Fair Value Measurements Using
 
Fair
Value
 
Quoted Prices
in Active
Markets
(Level 1)
 
Other
Observable
Inputs
(Level 2)
 
Unobservable
Inputs
(Level 3)
 
(in millions)
March 31, 2020
 
 
 
 
 
 
 
Cash equivalents
$
5,857

 
$
5,857

 
$

 
$

Debt securities:
 
 
 
 
 
 
 
U.S. Treasury and other U.S. government
corporations and agencies:
 
 
 
 
 
 
 
U.S. Treasury and agency obligations
398

 

 
398

 

Mortgage-backed securities
3,597

 

 
3,597

 

Tax-exempt municipal securities
1,553

 

 
1,553

 

Mortgage-backed securities:
 
 
 
 
 
 
 
Commercial
822

 

 
822

 

Asset-backed securities
1,081

 

 
1,081

 

Corporate debt securities
4,046

 

 
4,046

 

Total debt securities
11,497

 

 
11,497

 

Total invested assets
$
17,354

 
$
5,857

 
$
11,497

 
$

 
 
 
 
 
 
 
 
December 31, 2019
 
 
 
 
 
 
 
Cash equivalents
$
3,660

 
$
3,660

 
$

 
$

Debt securities:
 
 
 
 
 
 
 
U.S. Treasury and other U.S. government
corporations and agencies:
 
 
 
 
 
 
 
U.S. Treasury and agency obligations
354

 

 
354

 

Mortgage-backed securities
3,710

 

 
3,710

 

Tax-exempt municipal securities
1,463

 

 
1,463

 

Mortgage-backed securities:
 
 
 
 
 
 
 
Commercial
804

 

 
804

 

Asset-backed securities
1,093

 

 
1,093

 

Corporate debt securities
3,947

 

 
3,947

 

Total debt securities
11,371

 

 
11,371

 

Common stock
7

 
7

 

 

Total invested assets
$
15,038

 
$
3,667

 
$
11,371

 
$




Schedule of Assumptions Used For Inputs In Fair Value Measurement The table below presents the assumptions used for each reporting period.

 
March 31, 2020
December 31, 2019
Annualized volatility
28.0
%
19.8
%
Secured credit rate
4.1
%
2.2
%
NOPAT
12.0
%
12.0
%
Weighted average cost of capital
10.5
%
10.0
%
Long term growth rate
3.0
%
3.0
%